Cyclosporine A eye drops for symptomatic nummular keratitis: a retrospective case series
Session Details
Session Title: Cornea Medical II
Session Date/Time: Tuesday 13/09/2016 | 08:00-10:30
Paper Time: 08:30
Venue: Hall C3
First Author: : D.Cordeiro Sousa PORTUGAL
Co Author(s): : J. Pinto M. Canastro R. Amorim P. Guerra A. Quintas W. Rodrigues
Abstract Details
Purpose:
To describe and evaluate the use of topical cyclosporine A (CspA) 1% eye drops in the treatment of symptomatic nummular keratitis secondary to adenoviral keratoconjunctivitis resistant to standard topical corticosteroid therapy.
Setting:
Outpatient clinic - Ophthalmology, Lisbon Academic Medical Center.
Methods:
Retrospective case-series. A total of 12 eyes from 7 patients treated with 1% CspA (one drop t.i.d.) were reviewed. All patients had symptomatic nummular keratitis and were previously treated with topical corticosteroids with unsatisfactory response. Data collected included demographic data, duration of symptoms, length of treatment and clinical course at last follow-up visit. Only patients with complete clinical records were included.
Results:
Three males (43%) and four females (57%) with a mean age of 36.1 [range 8-66] years were included. Mean follow-up on CspA was 8.0 ± 6.5 months. Of the six (86%) patients who showed clinical improvement, 4 were dependent on CspA and 2 were better even after CspA tapering. One patient did not show any improvement with CspA eye drops. Most patients (87%) reported no adverse symptoms or reactions related to CspA treatment. Overall, patients were satisfied and noted a significant improvement in visual acuity.
Conclusions:
Although infrequently reported as such, 1% CspA eye drops could be a safe and effective option to consider in the treatment of symptomatic and corticosteroid-refractory nummular keratitis secondary to adenoviral keratoconjunctivitis. Further studies, with a prospective and controlled design should be pursued to clarify this indication.
Financial Disclosure:
NONE
